US20040092597A1 - Fenofibrate compositions having high bioavailability - Google Patents

Fenofibrate compositions having high bioavailability Download PDF

Info

Publication number
US20040092597A1
US20040092597A1 US10/665,517 US66551703A US2004092597A1 US 20040092597 A1 US20040092597 A1 US 20040092597A1 US 66551703 A US66551703 A US 66551703A US 2004092597 A1 US2004092597 A1 US 2004092597A1
Authority
US
United States
Prior art keywords
fenofibrate
minutes
composition
according
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/665,517
Inventor
Andre Stamm
Pawan Seth
Original Assignee
Andre Stamm
Pawan Seth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to FR9700479A priority Critical patent/FR2758459B1/en
Priority to FR9700479 priority
Priority to US09/005,128 priority patent/US6074670A/en
Priority to US09/572,330 priority patent/US6277405B1/en
Priority to US09/899,026 priority patent/US7037529B2/en
Priority to US10/078,500 priority patent/US6596317B2/en
Priority to US10/126,875 priority patent/US6589552B2/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9502710&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20040092597(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to US10/288,425 priority patent/US6652881B2/en
Priority to US10/290,333 priority patent/US7041319B2/en
Application filed by Andre Stamm, Pawan Seth filed Critical Andre Stamm
Priority to US10/665,517 priority patent/US20040092597A1/en
Publication of US20040092597A1 publication Critical patent/US20040092597A1/en
Assigned to PAUL ROYALTY FUND HOLDINGS II reassignment PAUL ROYALTY FUND HOLDINGS II GRANT OF A SECURITY INTEREST IN GRANTOR'S (DEBTOR'S) LICENSE RIGHTS TO GRANTEE (SECURED PARTY) (SEE DOCUMENT FOR DETAILS) Assignors: GUARDIAN II ACQUISITION CORPORATION
Application status is Abandoned legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Abstract

The invention provides fenofibrate compositions having a dissolution of at least 10% in 5 minutes, 20% in 10 minutes, 50% in 20 minutes and 75% in 30 minutes, as measured using the rotating blade method at 75 rpm according to the European Pharmacopoeia, in a dissolution medium constituted by water with 2% by weight polysorbate 80 or a dissolution medium constituted by water with 0.025 M sodium lauryl sulfate.

Description

    RELATED APPLICATIONS
  • This application is a continuation of U.S. application Ser. No. 10/288,425 filed Nov. 6, 2002; which is a continuation of U.S. application Ser. No. 10/126,875 filed Apr. 22, 2002, issued as U.S. Pat. No. 6,589,552; which is a continuation of U.S. application Ser. No. 10/078,500 filed Feb. 21, 2002, issued as U.S. Pat. No. 6,596,317; which is a continuation of U.S. application Ser. No. 09/899,026 filed Jul. 6, 2001; which is a continuation of U.S. application Ser. No. 09/572,330 filed May 18, 2000, issued as U.S. Pat. No. 6,277,405; which is a continuation of U.S. application Ser. No. 09/005,128 filed Jan. 9, 1998, issued as U.S. Pat. No. 6,074,670; which claims priority to French Application No. 97 00 479 filed Jan. 17, 1997. This application is also a continuation of U.S. application Ser. No. 10/290,333 filed Nov. 8, 2002.[0001]
  • BACKGROUND OF THE INVENTION
  • The present invention relates to a novel pharmaceutical composition having high bioavailability through improved dissolution, and a method for preparing it. The invention more particularly relates to a pharmaceutical composition for administration by oral route, containing an active ingredient of poor aqueous solubility. [0002]
  • Numerous active ingredients suffer from the disadvantage of being poorly soluble in an aqueous medium, thus having an insufficient dissolution profile and, consequently, poor bioavailability within the organism, following oral administration. The therapeutic dose required to be administered must thus be increased in order to obviate this disadvantage. This particularly applies to numerous hypolipemiant active ingredients, such as those belonging to the fibrate family. [0003]
  • Fenofibrate is a well-known hypolipemiant from the family of fibrates, which is commercially available in various doses (100 and 300 mg for example Secalip®) but in a form leading to poor bioavailability of the active ingredient. Indeed, due to it poor hydrosolubility, fenofibrate is poorly absorbed in the digestive tract and consequently its bioavailability is incomplete, irregular and often varies from one person to another. [0004]
  • To improve the dissolution profile of fenofibrate and its bioavailability, thereby reducing the dose requiring to be administered, it would be useful to increase its dissolution so that it could attain a level close to 100%. [0005]
  • Moreover, for patient comfort, it is advantageous to seek a dosage form that only requires the medicament to be taken once daily while giving the same effect as one administered several times daily. [0006]
  • EP-A-0330532 discloses a method for improving bioavailability of fenofibrate. This patent describes the effect of co-micronizing fenofibrate with a surfactant, for example sodium laurylsulfate in order to improve fenofibrate solubility and thereby increase its bioavailability. This patent teaches that co-micronizing fenofibrate with a solid surfactant improves fenofibrate bioavailability to a much greater extent than the improvement that would be obtained either by adding a surfactant, or through solely micronizing the fenofibrate, or, yet again, through intimately mixing the fenofibrate and surfactant, micronized separately. The dissolution method employed is the conventional rotating blade technique (European Pharmacopoeia): product dissolution kinetics are measured in a fixed volume of the dissolution medium, agitated by means of a standardized device; a test was also carried out with an alternative technique to the European Pharmacopoeia, using the continuous-flow cell method. [0007]
  • The process of EP-A-0330532 leads to a new dosage form in which the active ingredient, co-micronized with a solid surfactant, has improved fenofibrate dissolution, and thus increased bioavailability, which makes it possible, for a given level of effectiveness, to decrease the daily dose of the medicament: respective 67 mg and 200 mg instead of 100 mg and 300 mg. [0008]
  • However, the preparation method in that patent is not completely satisfactory inasmuch as it does not lead to complete bioavailability of the active ingredient, and suffers from several disadvantages. The technique of co-micronizing fenofibrate with a solid surfactant does, it is true, improve dissolution of the active ingredient, but this dissolution remains, however, incomplete. [0009]
  • There is thus a need to improve fenofibrate bioavailability in order to attain, over very short periods of time, a level close to 100% (or, in any case, better than the following limits: 10% in 5 minutes, 20% in 10 minutes, 50% in 20 minutes and 75% in 30 minutes in a medium consisting of 1200 ml water to which 2% Polysorbate 80 is added, or of 1000 ml of water to which 0.025M sodium lauryl sulfate sodium is added, with a blade rotation speed of 75 rpm), and this even when dissolution media having a low surfactant content are used. [0010]
  • Applicant has found that, surprisingly, it is possible to resolve this problem by a new method for preparing a pharmaceutical composition by spraying a suspension of the active ingredient onto an inert hydrosoluble carrier. The present invention also relates to pharmaceutical compositions thus prepared. [0011]
  • The use is already known of a polymer, such as polyvinylpyrrolidone for producing tablets, in concentrations of the order of 0.5 to 5% by weight, at a maximum 10% by weight. In this case, the polyvinylpyrrolidone is used as a binder. Similarly, the use of a polymer such as hydroxymethylpropylmethyl cellulose as a granulation binder is known. Thus, European patent application 0,519,144 discloses pellets of a poorly soluble substance, omeprazole, obtained by spraying a dispersion or suspension of the active ingredient in a solution containing said polymer onto inert pellets in a fluidized-bed granulator. However, here again, the polymer (HPMC and HPC) is only used as a granulation binder, in an amount of about 50% by weight, based on the weight of the active ingredient, which, bearing in mind the presence of the inert pellets of a large size (about 700 μm) and the overall final weight leads to final active ingredient and polymer contents which are very low, of the order of barely a few percent based on the weight of the final covered pellet. Finally, it will be noted that the size of the inert pellets in this documents is fairly large, which, in the case of fenofibrate, would lead to a final formulation having a volume which is much too large for ready oral administration. [0012]
  • The use of polymer, such as polyvinylpyrrolidone for manufacturing “solid dispersions” is also known, obtained in general by co-precipitation, co-fusion or liquid-phase mixing followed by drying. What we have here is fixation of the active ingredient in isolated microparticles on the polyvinylpyrrolidone, which avoids problems of poor wetting of the solid and re-agglomeration of the particles. The article “Stable Solid Dispersion System Against Humidity” by Kuchiki et al., Yakuzaigaku, 44 No. 1, 31-37 (1984) describes such a technique for preparing solid dispersions using polyvinylpyrrolidone. The amounts of PVP here are very high, and the ratio between the active ingredient and PVP are comprised between 1/1 and 1/20. In the case however there is no inert carrier. [0013]
  • WO-A-96 01621 further discloses a sustained release composition, comprising an inert core (silica in all examples) coated with a layer which contains the active ingredient in admixture with a hydrophilic polymer, the weight ratio active ingredient/polymer being comprised between 10/1 and 1/2 and the weight ratio active ingredient/inert core being comprised between 5/1 and 1/2, with an outer layer to impart the sustained release property. These compositions can be compressed. The hydrophilic polymer can be polyvinylpyrrolidone. This document also discloses a process for preparing said composition; for example in a fluidized-bed granulator one will spray a dispersion of active ingredient in a polymer solution onto the inert cores. This document solely relates to sustained release compositions, the technical problem to be solved being the compression, without damages, of the outer layer imparting the sustained release property. [0014]
  • Nevertheless, nothing in the state of the art teaches nor suggest the present invention. [0015]
  • SUMMARY OF THE INVENTION
  • Thus, the present invention provides an immediate-release fenofibrate composition comprising: [0016]
  • (a) an inert hydrosoluble carrier covered with at least one layer containing a fenofibrate active ingredient in a micronized form having a size less than 20 μm, a hydrophilic polymer and, optionally, a surfactant; said hydrophilic polymer making up at least 20% by weight of (a); and [0017]
  • (b) optionally one or several outer phase(s) or layer(s). [0018]
  • In one embodiment, a surfactant is present with the active ingredient and the hydrophilic polymer. [0019]
  • The invention also provides a composition comprising fenofibrate having a dissolution of at least 10% in 5 minutes, 20% in 10 minutes, 50% in 20 minutes and 75% in 30 minutes, as measured using the rotating blade method at 75 rpm according to the European Pharmacopoeia, in a dissolution medium constituted by water with 2% by weight polysorbate 80 or in a dissolution medium constituted by water with 0.025M sodium lauryl sulfate. [0020]
  • A method for preparing a pharmaceutical composition is also provided, comprising the steps of: [0021]
  • (a) preparing a fenofibrate suspension in micronized form with a particle size below 20 μm, in a solution of hydrophilic polymer and, optionally surfactant; [0022]
  • (b) applying the suspension from step (a) to an inert hydrosoluble carrier; [0023]
  • (c) optionally, coating granules thus obtained with one or several phase(s) or layer(s). [0024]
  • Step (b) is preferably carried out in a fluidized-bed granulator. [0025]
  • The method can comprise a step in which products obtained from step (b) or (c) are compressed, with or without additional excipients. [0026]
  • The invention also provides a suspension of fenofibrate in micronized form having a size less than 10 μm, in a solution of hydrophilic polymer and, optionally, surfactant. [0027]
  • The invention will be described in more detail in the description which follows, with reference to the attached drawings.[0028]
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a graph of a comparative study of the dissolution profile of a composition according to the invention, compared to that of Lipanthyl® 200M; [0029]
  • FIG. 2 is a graph illustrating a comparative study of the dissolution profile of a composition according to the invention and that of pharmaceutical products commercially available on the German market.[0030]
  • DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
  • The expression “in micronized form” in this invention means a substance in a particulate form, the dimensions of the particles being less than or equal to about 20 μm. [0031]
  • Advantageously, this dimension is less than or equal to 10 μm. [0032]
  • In the framework of this invention, the expression “inert hydrosoluble carrier” means any excipient, generally hydrophilic, pharmaceutically inert, crystalline or amorphous, in a particulate form, not leading to a chemical reaction under the operating conditions employed, and which is soluble in an aqueous medium, notably in a gastric acid medium. Examples of such excipients are derivatives of sugars, such as lactose, saccharose, hydrolyzed starch (malto-dextrine), etc. Mixture are also suitable. The individual particle size of the inert hydrosoluble carrier can be, for example, between 50 and 500 micron. [0033]
  • The expression “hydrophilic polymer” in the invention should be taken to mean any high molecular weight substance (greater, for example, than 300) having sufficient affinity towards water to dissolve therein and form a gel. Examples of such polymers are polyvinylpyrrolidone, poly(vinyl alcohol), hydroxypropylcellulose, hydroxymethylcellulose, hydroxypropylmethylcellulose, gelatin, etc. Polymer blends are also suitable. [0034]
  • The preferred hydrophilic polymer is polyvinylpyrrolidone (PVP). The PVP used in this invention has, for example, a molecular weight comprised between 10,000 and 100,000, preferably for example between 20,000 and 55,000. [0035]
  • The term “surfactant” is used in its conventional sense in this invention. Any surfactant is suitable, whether it be amphoteric, non-ionic, cationic or anionic. Examples of such surfactants are: sodium lauryl sulfate, monooleate, monolaurate, monopalmitate, monostearate or another ester of polyoxyethylene sorbitane, sodium dioctylsulfosuccinate (DOSS), lecithin, stearylic alcohol, cetostearylic alcohol, cholesterol, polyoxyethylene ricin oil, polyoxyethylene fatty acid glycerides, poloxamer®, etc. Mixtures of surfactants are also suitable. [0036]
  • The preferred surfactant is sodium laurylsulfate, which can be co-micronized with fenofibrate. [0037]
  • The compositions according to the invention can additionally contain any excipient conventionally used in the pharmaceutical and chemical fields which is compatible with the active ingredient, such as binders, fillers, pigments, disintegrating agents, lubricants, wetting agents, buffers, etc. As examples, excipients able to be used in this invention we can cite: microcrystalline cellulose, lactose, starch, colloidal silica, talc, glycerol esters, sodium stearyl fumarate, titanium dioxide, magnesium stearate, stearic acid, cross-linked polyvinyl pyrrolidone (AC DI SOL®), carboxymethyl starch (Explotab®, Primojel®), hydroxypropylcellulose, hydroxymethylcellulose, hydroxypropylmethylcellulose, gelatin, etc. [0038]
  • Here, the expression “outer phase or layer” should be taken to mean any coating on the element (a) with the active ingredient (forming a “core”). Indeed, it can be useful to have available one or several phase(s) or layer(s) on top of the coated core. The invention thus covers a single core with one layer, but also several cores in a phase, as is the case of tablets which are formed from “cores” mixed with a phase. [0039]
  • This outer layer comprises conventional excipients. [0040]
  • It is also possible to provide a layer comprising additives, for the manufacture of tablets. In this embodiment, the outer layer comprises a disintegration agent and, for example, a lubricant; the thus covered and mixed granules can then be readily compressed and easily disintegrate in water. [0041]
  • The compositions according to the invention comprise, in general, based on the total composition weight excluding the outer phase or layer, an inert hydrosoluble carrier making up from 10 to 80% by weight, preferably 20 to 50% by weight, the fenofibrate representing from 5 to 50% by weight, preferably from 20 to 45% by weight, the hydrophilic polymer representing from 20 to 60% by weight, preferably 25 to 45% by weight, the surfactant making up from 0 to 10% by weight, preferably 0.1 to 3% by weight. [0042]
  • The outer layer or phase if present, can make up to 80% by weight of the total weight, preferably up to 50% by weight. [0043]
  • The hydrophilic polymer represents preferably more than 25% by weight, based on the weight of (a). [0044]
  • The weight ratio of fenofibrate/hydrophilic polymer can for example be comprised between 1/10 and 4/1, preferably, for example, between 1/2 and 2/1. [0045]
  • When a surfactant is employed, the weight ratio surfactant/hydrophilic polymer can be comprised for example between 1/500 and 1/10, preferably, for example, between 1/100 and 5/100. [0046]
  • In one embodiment, the composition according to the invention takes the form of tablets. [0047]
  • This tablet preferably results from the compression of elements (a) (under the form of granules) together with an outer phase. [0048]
  • In another embodiment, the composition of the invention takes the form of granules enclosed inside a capsule, for example in gelatin, or inside a bag. [0049]
  • The compositions of the invention are particularly suitable for administering active ingredients by oral route. [0050]
  • The composition according to the invention is prepared by a novel process comprising spraying a suspension of the active ingredient in a micronized form in a solution of a hydrophilic polymer and, optionally, a surfactant, onto the inert core. [0051]
  • When a surfactant is present, the active ingredient can be co-micronized with the surfactant. One will then use with advantage the teachings of EP-A-0330532. [0052]
  • The method according to the invention consists in using the fluidized bed granulation principle, but with specific starting materials, in order to arrive at an improved dissolution profile and thus, at elevated bioavailability. In particular, the invention employs a suspension of the micronized active ingredient in a solution of a hydrophilic polymer and, optionally, a surfactant. [0053]
  • The fluidized-bed granulation technique is widely used in the pharmaceutical industry for preparing capsules or tablets. Conventionally, according to the prior art, a powder or a mixture of powders (active ingredient+excipients) is put into suspension in the fluidized bed in a granulator, and a solution containing a binder and, optionally, a surfactant, is sprayed onto this bed to form granules. The fluidized-bed granulation technique is well known to those skilled in the art and reference should be made to standard works such as for example “Die Tablette”, by Ritschel, Ed. Cantor Aulendorf, pages 211-212. [0054]
  • The invention, as has been indicated, comprises spraying a suspension of an active ingredient micronized with a hydrophilic polymer onto an inert carrier. Following granulation, the granulate formed consists of crystals of, for example, lactose, which are isolated (or possibly agglomerated together by the spray solution) and particles of active ingredient and PVP adhering to the crystal surface. The granule could similarly be constituted of coated crystals which are agglomerated, or even of such an agglomerate having received a coating. [0055]
  • The compositions according to the invention can also be prepared by other methods, for example by spraying a solution of the micronized active ingredient onto the hydrosoluble inert carrier. [0056]
  • The granulates thus obtained can, if desired, be provided with an outer coating or compressed into tablets, or form agglomerates. [0057]
  • The outer layer or layer is/are applied using conventional coating techniques such as coating in a pan or fluidized bed coater. [0058]
  • When the granulate obtained (whether subsequently coated or not) is compressed to form tablets, this step can be implemented using any conventional technique which is suitable, for example using an alternating or rotating compressing equipment. [0059]
  • The significant starting product is the suspension of the active ingredient. This suspension is prepared by putting the micronized active ingredient into suspension in a solution comprising the hydrophilic polymer and, optionally, a surfactant, in solution in a solvent. If a surfactant is employed, it is put into solution in the solvent (beaker+magnetic or vane stirrer). Next, the hydrophilic polymer (PVP) is dispersed, while stirring, in the solution previously obtained. Depending on polymer solubility, this either dissolves in the solution or forms a gel or a suspension having varying degrees of thickness. While still stirring, the micronized active ingredient is dispersed in the form of a fine shower into the above solution or suspension, to form a homogeneous suspension. The order of these steps can be reversed. The solvent employed can be aqueous or organic (for example ethanol). For example demineralized water can be used. [0060]
  • The active ingredient concentration in the suspension is from 1 to 40% by weight, preferably from 10 to 25%. [0061]
  • The hydrophilic polymer concentration in the suspension is from 5 to 40% by weight, preferably 10 to 25%. [0062]
  • The surfactant concentration in the suspension is from 0 to 10% by weight, preferably below 5%. [0063]
  • The invention also covers this novel suspension. [0064]
  • Without wishing to be tied down to a specific theory, applicant believes that this novel method, through the use of a micronized active ingredient suspension in a hydrophilic polymer solution, enabled a novel composition to be obtained in which the active ingredient is in a non-re-agglomerated form. [0065]
  • The following examples illustrate the invention without limiting it. [0066]
  • EXAMPLE 1
  • Preparation of a pharmaceutical composition of fenofibrate according to the invention. [0067]
  • A composition containing, as the element a), micronized fenofibrate, Plasdone®, Capsulac® and sodium lauryl sulfate was prepared. [0068]
  • The micronized fenofibrate had a particle size of about 5 μm, as measured using a Coulter counter. [0069]
  • The Plasdone K25® corresponds to a polyvinylpyrrolidone PVP ISP and the Capsulac 60® corresponds to a coarse crystal lactose monohydrate (Meggle) (particle size between 100 and 400 μm). [0070]
  • The sodium laurylsulfate (7 g) is dissolved in water (demineralized water, 1750 g) and the micronized fenofibrate (350 g) is put into suspension in the mixture obtained (for example using a helix stirrer at 300 rpm for 10 minutes, then using an Ultra Turrax agitator at 10,000 rpm, for 10 minutes). Following this, the PVP (350 g) is added while still agitating, stirring (helix stirrer) being continued until the latter had dissolved (30 minutes). It is all passed through a sieve (350 μm) to eliminate possible agglomerates. [0071]
  • Separately, the lactose (400 g) is put into suspension in a fluidized air bed granulator (of the Glatt® GPCG1—Top Spray type or equivalent) and heated to a temperature of 40° C. [0072]
  • The fenofibrate suspension is sprayed onto the lactose. This step is carried out under the following conditions: spraying pressure: 2.1 bar, air throughput 70 m[0073] 3/h, air inlet temperature: 45° C.; air outlet temperature: 33° C.; product temperature 34° C.; duration of spraying: 3 h.
  • The granulate thus obtained can be put inside capsules or transformed into tablets. Any suitable conventional technique for preparing such dosage forms can be used. [0074]
  • For transformation to tablet form, one will mix 191 g of the granulate obtained (using for example a mixer-grinder type mixing apparatus, a planetary mixer or turn-over mixer), with the outer phase having the following composition: [0075]
  • 56 g Polyplasdone XL® (cross-linked polyvinylpyrrolidone ISP, as described in the U.S.A Pharmacopoeia “U.S.P-NF” under the name of crospovidone, mean molecular weight>1,000,000); [0076]
  • 88 g Avicel® PH200 (microcrystalline cellulose); [0077]
  • 3.5 g sodium stearyl fumarate (Mendell, U. S. A.); and [0078]
  • 2 g Aerosil® 200 (colloidal silica). [0079]
  • The cross-linked polyvinylpyrrolidone, the microcrystalline cellulose, the sodium stearyl fumarate and the colloidal silica are respectively, disintegration agents, binders, lubricating and flow enhancing agents. [0080]
  • The tablet can be obtained on an alternating compression machine (for example Korsch EKO) or a rotary machine (for example Fette Perfecta 2). [0081]
  • One thus obtains tablets having the following composition, expressed in mg: [0082]
    element (a):
    micronized fenofibrate 100.0
    PVP 100.0
    Lactose 114.3
    sodium laurylsulfate 2.0
    outer phase (or layer):
    cross-linked PVP 92.7
    microcrystalline cellulose 145.7
    sodium stearyl fumarate 5.8
    colloidal silica 3.3
  • EXAMPLE 2
  • Dissolution of a composition according to the invention and a composition according to the prior art. [0083]
  • a) Dissolution Medium and Procedure for Measuring Dissolution. [0084]
  • A dissolution medium which is discriminating, in other words one in which two products having very different dissolution profiles in gastric juices will have very different dissolution curves is looked for. [0085]
  • For this, an aqueous medium containing a surfactant, this being Polysorbate 80 (polyoxyethylene sorbitane mono-oleate) is used. This surfactant is readily available from various suppliers, is the object of a monograph in the Pharmacopoeias, and is thus easy to implement (being also a water-soluble liquid product). Other surfactants can also be used. [0086]
  • The rotating blade method (European Pharmacopoeia) is used under the following conditions: volume of medium: 1200 ml; medium temperature: 37° C.; blade rotation speed: 75 rpm; samples taken: every 2.5 minutes. Determination of the amount dissolved is carried out by spectrophotometry. Test are repeated 6 times over. [0087]
  • b) Results [0088]
  • The composition according to the invention consisted of two tablets containing about 100 mg fenofibrate prepared according to Example 1. [0089]
  • The prior art composition was Lipanthyl® 200M from Laboratoires Fournier, containing 200 mg fenofibrate (corresponding to capsules of 200 mg fenofibrate, co-micronized with sodium laurylsulfate, and containing lactose, pre-gelatinized starch, cross-linked polyvinylpyrrolidone and magnesium stearate, in line with the teachings of EP-A-0330532). [0090]
  • The results obtained are shown graphically in FIG. 1, on which the percentage of dissolution is shown, the observed standard deviation being indicated between brackets. [0091]
  • These results clearly show that the compositions according to the invention have a dissolution profile which is distinctly better than that of the prior art compositions. [0092]
  • These results also clearly show that with the compositions of the invention, the standard deviation observed is distinctly lower than is the case with prior art compositions. [0093]
  • EXAMPLE 3
  • Study of bioavailability of compositions according to the invention and prior art compositions. [0094]
  • A test of bioavailability on healthy volunteers was carried out. [0095]
  • The following compositions were tested: [0096]
  • composition according to the invention: capsules containing granules prepared according to example 1, containing 200 mg fenofibrate. [0097]
  • first composition according to the prior art: Lipanthyl® 200M from Laboratoires Fournier, containing 200 mg fenofibrate, identical to that in the previous example. [0098]
  • second prior art composition: Secalip® in capsule form (300 mg fenofibrate in the form of three 100 mg capsules). [0099]
  • The study was carried out on 6 healthy volunteers receiving a single dose of fenofibrate, with a minimum 6-day rest period between administrations. The samples for pharmaco-kinetic analysis were collected after each administration at the following times: 0.5 h; 1 h; 2 h; 3 h; 4 h; 5 h; 6 h; 8 h; 10 h; 12 h; 24 h; 36 h; 48 h; 72 h; and 96 hours following administration of the medicament. Fenofibric acid content in plasma was measured for each sample. [0100]
  • The results obtained are given in table 1 below. [0101]
    TABLE 1
    dose Cmax tmax AUG 0-t AUG 0-∞
    Product (mg) (μg/ml) (h) t ½ (h) (μg.h/ml) (μg.h/ml)
    Invention 200 5.4 6 23 148 162
    Secalip ® 3 × 100 1.1 25 39 53 56
    100
    Lipanthyl ® 200 1.6 8.3 41 71 92
    200 M
  • The results clearly show that the compositions of the present invention have a dissolution profile that is an improvement over compositions of the prior art, leading to a considerably enhanced bioavailability of the active ingredient compared to that obtained with compositions of the prior art. [0102]
  • EXAMPLE 4
  • Comparison of the dissolution profile of compositions according to the invention and that of products currently on the German market. [0103]
  • On the German market, immediate or sustained-release fenofibrate formulations exist. Like in France, the 100 mg and 300 mg (conventional) forms coexist with 67 and 200 mg forms (having enhanced bioavailability, according to the teaching of EP-A-0330532). These products are as follows: [0104]
  • Fenofibrate-ratiopharm; Ratiopharm-Ulm; [0105]
  • Capsules; [0106]
  • Composition: 100 mg fenofibrate; [0107]
  • Excipients: lactose, corn starch, magnesium stearate, E 171 colorant, gelatine. [0108]
  • Durafenat; Durachemie—Wolfratshausen Capsules; [0109]
  • Composition: 100 mg fenofibrate; [0110]
  • Excipients: lactose, corn starch, magnesium stearate, E 171 colorant, gelatine. [0111]
  • Normalip pro; Knoll—Ludwigshafen; [0112]
  • Capsules; [0113]
  • Composition: 200 mg Fenofibrate; [0114]
  • Excipients: Crospovidone, gelatine, monohydrate lactose, magnesium stearate, corn starch, sodium laurylsulfate, E 132 and E 171 colorants. [0115]
  • A comparison was made between: [0116]
  • the tablet of the invention as prepared using example 1 (2×100 mg) [0117]
  • Normalip pro® (200 mg); [0118]
  • Lipanthyl® 200M (200 mg) (according to the preceding example); [0119]
  • Fenofibrate by Ratiopharm® (2×100 mg); [0120]
  • Durafenat® (2×100 mg) [0121]
  • The tests were implemented under the same conditions as in the previous examples. FIG. 2 summarizes the results. [0122]
  • These results clearly show that the compositions of the invention have a distinctly improved dissolution compared to prior art compositions. [0123]
  • Obviously, the present invention is not limited to the embodiments described but may be subject to numerous variations readily accessible to those skilled in the art. [0124]

Claims (56)

What is claimed is:
1. A composition comprising fenofibrate and at least one pharmaceutical excipient, wherein the composition has a dissolution of at least 10% in 5 minutes, 20% in 10 minutes, 50% in 20 minutes and 75% in 30 minutes, as measured using the rotating blade method at 75 rpm according to the European Pharmacopoeia, in a dissolution medium constituted by water with 2% by weight polysorbate 80 or 0.025 M sodium lauryl sulfate.
2. The composition according to claim 1, wherein the at least one pharmaceutical excipient is at least one binder, at least one filler, at least one pigment, at least one disintegrating agent, at least one lubricant, at least one wetting agent, at least one buffer, or a mixture of two or more thereof.
3. The composition according to claim 1, wherein the at least one pharmaceutical excipient is at least one disintegrating agent.
4. The composition according to claim 1, wherein the at least one pharmaceutical excipient is selected from the group consisting of microcrystalline cellulose, lactose, starch, colloidal silica, talc, glycerol esters, sodium stearyl fumarate, titanium dioxide, magnesium stearate, stearic acid, cross-linked polyvinyl pyrrolidone, carboxymethyl starch, hydroxypropylcellulose, hydroxymethylcellulose, hydroxypropylmethylcellulose, gelatin, and a mixture of two or more thereof.
5. The composition of claim 1, wherein the fenofibrate is present in an amount of 5 to 50% by weight.
6. The composition of claim 1, wherein the fenofibrate is present in an amount of 20 to 45% by weight.
7. The composition of claim 1 in the form of a tablet.
8. The composition of claim 1 in the form of a capsule.
9. A composition comprising fenofibrate, at least one inert carrier and at least one pharmaceutical excipient, wherein the composition has a dissolution of at least 10% in 5 minutes, 20% in 10 minutes, 50% in 20 minutes and 75% in 30 minutes, as measured using the rotating blade method at 75 rpm according to the European Pharmacopoeia, in a dissolution medium constituted by water with 2% by weight polysorbate 80 or 0.025 M sodium lauryl sulfate.
10. The composition according to claim 9, wherein the at least one pharmaceutical excipient is at least one binder, at least one filler, at least one pigment, at least one disintegrating agent, at least one lubricant, at least one wetting agent, at least one buffer, or a mixture of two or more thereof.
11. The composition according to claim 9, wherein the at least one pharmaceutical excipient is at least one disintegrating agent.
12. The composition according to claim 9, wherein the at least one pharmaceutical excipient is selected from the group consisting of microcrystalline cellulose, lactose, starch, colloidal silica, talc, glycerol esters, sodium stearyl fumarate, titanium dioxide, magnesium stearate, stearic acid, cross-linked polyvinyl pyrrolidone, carboxymethyl starch, hydroxypropylcellulose, hydroxymethylcellulose, hydroxypropylmethylcellulose, gelatin, and a mixture of two or more thereof.
13. The composition of claim 9, wherein the fenofibrate is present in an amount of 5 to 50% by weight.
14. The composition of claim 9, wherein the fenofibrate is present in an amount of 20 to 45% by weight.
15. The composition of claim 9 in the form of a tablet.
16. The composition of claim 9 in the form of a capsule.
17. An orally administrable tablet comprising fenofibrate and at least one pharmaceutical excipient, wherein the tablet has a dissolution of at least 10% in 5 minutes, 20% in 10 minutes, 50% in 20 minutes and 75% in 30 minutes, as measured using the rotating blade method at 75 rpm according to the European Pharmacopoeia, in a dissolution medium constituted by water with 2% by weight polysorbate 80 or a dissolution medium constituted by water with 0.025 M sodium lauryl sulfate.
18. The tablet according to claim 17, wherein the at least one pharmaceutical excipient is at least one binder, at least one filler, at least one pigment, at least one disintegrating agent, at least one lubricant, at least one wetting agent, at least one buffer, or a mixture of two or more thereof.
19. The tablet according to claim 17, wherein the at least one pharmaceutical excipient is at least one disintegrating agent.
20. The tablet according to claim 17, wherein the at least one pharmaceutical excipient is selected from the group consisting of microcrystalline cellulose, lactose, starch, colloidal silica, talc, glycerol esters, sodium stearyl fumarate, titanium dioxide, magnesium stearate, stearic acid, cross-linked polyvinyl pyrrolidone, carboxymethyl starch, hydroxypropylcellulose, hydroxymethylcellulose, hydroxypropylmethylcellulose, gelatin, and a mixture of two or more thereof.
21. The tablet according to claim 17, wherein the fenofibrate is present in an amount of 5 to 50% by weight.
22. The tablet according to claim 17, wherein the fenofibrate is present in an amount of 20 to 45% by weight.
23. An orally administrable capsule comprising fenofibrate and at least one pharmaceutical excipient, wherein the capsule has a dissolution of at least 10% in 5 minutes, 20 % in 10 minutes, 50% in 20 minutes and 75% in 30 minutes, as measured using the rotating blade method at 75 rpm according to the European Pharmacopoeia, in a dissolution medium constituted by water with 2% by weight polysorbate 80 or a dissolution medium constituted by water with 0.025 M sodium lauryl sulfate.
24. The capsule according to claim 23, wherein the at least one pharmaceutical excipient is at least one binder, at least one filler, at least one pigment, at least one disintegrating agent, at least one lubricant, at least one wetting agent, at least one buffer, or a mixture of two or more thereof.
25. The capsule according to claim 23, wherein the at least one pharmaceutical excipient is at least one disintegrating agent.
26. The capsule according to claim 23, wherein the at least one pharmaceutical excipient is selected from the group consisting of microcrystalline cellulose, lactose, starch, colloidal silica, talc, glycerol esters, sodium stearyl fumarate, titanium dioxide, magnesium stearate, stearic acid, cross-linked polyvinyl pyrrolidone, carboxymethyl starch, hydroxypropylcellulose, hydroxymethylcellulose, hydroxypropylmethylcellulose, gelatin, and a mixture of two or more thereof.
27. The capsule according to claim 23, wherein the fenofibrate is present in an amount of 5 to 50% by weight.
28. The capsule according to claim 23, wherein the fenofibrate is present in an amount of 20 to 45% by weight.
29. A composition comprising fenofibrate and at least one disintegrating agent, wherein the composition has a dissolution of at least 10% in 5 minutes, 20% in 10 minutes, 50% in 20 minutes and 75% in 30 minutes, as measured using the rotating blade method at 75 rpm according to the European Pharmacopoeia, in a dissolution medium constituted by water with 2% by weight polysorbate 80 or 0.025 M sodium lauryl sulfate.
30. The composition according to claim 29, wherein the at least one disintegrating agent is selected from the group consisting of starch, colloidal silica, cross-linked polyvinyl pyrrolidone and carboxymethyl starch, and a mixture of two or more thereof.
31. The composition of claim 29, wherein the fenofibrate is present in an amount of 5 to 50% by weight.
32. The composition of claim 29, wherein the fenofibrate is present in an amount of 20 to 45% by weight.
33. The composition of claim 29 in the form of a tablet.
34. The composition of claim 29 in the form of a capsule.
35. A composition comprising fenofibrate, at least one inert carrier and at least one disintegrating agent, wherein the composition has a dissolution of at least 10% in 5 minutes, 20% in 10 minutes, 50% in 20 minutes and 75% in 30 minutes, as measured using the rotating blade method at 75 rpm according to the European Pharmacopoeia, in a dissolution medium constituted by water with 2% by weight polysorbate 80 or 0.025 M sodium lauryl sulfate.
36. The composition according to claim 35, wherein the at least one disintegrating agent is selected from the group consisting of starch, colloidal silica, cross-linked polyvinyl pyrrolidone and carboxymethyl starch, and a mixture of two or more thereof.
37. The composition of claim 35, wherein the fenofibrate is present in an amount of 5 to 50% by weight.
38. The composition of claim 35, wherein the fenofibrate is present in an amount of 20 to 45% by weight.
39. The composition of claim 35 in the form of a tablet.
40. The composition of claim 35 in the form of a capsule.
41. An orally administrable tablet comprising fenofibrate and at least one disintegrating agent, wherein the tablet has a dissolution of at least 10% in 5 minutes, 20% in 10 minutes, 50% in 20 minutes and 75% in 30 minutes, as measured using the rotating blade method at 75 rpm according to the European Pharmacopoeia, in a dissolution medium constituted by water with 2% by weight polysorbate 80 or a dissolution medium constituted by water with 0.025 M sodium lauryl sulfate.
42. The tablet according to claim 41, wherein the at least one disintegrating agent is selected from the group consisting of starch, colloidal silica, cross-linked polyvinyl pyrrolidone and carboxymethyl starch, and a mixture of two or more thereof.
43. The tablet according to claim 41, wherein the fenofibrate is present in an amount of 5 to 50% by weight.
44. The tablet according to claim 41, wherein the fenofibrate is present in an amount of 20 to 45% by weight.
45. An orally administrable capsule comprising fenofibrate and at least one disintegrating agent, wherein the capsule has a dissolution of at least 10% in 5 minutes, 20% in 10 minutes, 50% in 20 minutes and 75% in 30 minutes, as measured using the rotating blade method at 75 rpm according to the European Pharmacopoeia, in a dissolution medium constituted by water with 2% by weight polysorbate 80 or a dissolution medium constituted by water with 0.025 M sodium lauryl sulfate.
46. The capsule according to claim 45, wherein the at least one disintegrating agent is selected from the group consisting of starch, colloidal silica, cross-linked polyvinyl pyrrolidone and carboxymethyl starch, and a mixture of two or more thereof.
47. The capsule according to claim 45, wherein the fenofibrate is present in an amount of 5 to 50% by weight.
48. The capsule according to claim 45, wherein the fenofibrate is present in an amount of 20 to 45% by weight.
49. The composition according to claim 1, wherein the fenofibrate is in a non-reagglomerated form.
50. The composition according to claim 9, wherein the fenofibrate is in a non-reagglomerated form.
51. The tablet according to claim 17, wherein the fenofibrate is in a non-reagglomerated form.
52. The capsule according to claim 23, wherein the fenofibrate is in a non-reagglomerated form.
53. The composition according to claim 29, wherein the fenofibrate is in a non-reagglomerated form.
54. The composition according to claim 35, wherein the fenofibrate is in a non-reagglomerated form.
55. The tablet according to claim 41, wherein the fenofibrate is in a non-reagglomerated form.
56. The capsule according to claim 45, wherein the fenofibrate is in a non-reagglomerated form.
US10/665,517 1997-01-17 2003-09-22 Fenofibrate compositions having high bioavailability Abandoned US20040092597A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
FR9700479A FR2758459B1 (en) 1997-01-17 1997-01-17 The pharmaceutical composition of fenofibrate having a high bioavailability and process for its preparation
FR9700479 1997-01-17
US09/005,128 US6074670A (en) 1997-01-17 1998-01-09 Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it
US09/572,330 US6277405B1 (en) 1997-01-17 2000-05-18 Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it
US09/899,026 US7037529B2 (en) 1997-01-17 2001-07-06 Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it
US10/078,500 US6596317B2 (en) 1997-01-17 2002-02-21 Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it
US10/126,875 US6589552B2 (en) 1997-01-17 2002-04-22 Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it
US10/288,425 US6652881B2 (en) 1997-01-17 2002-11-06 Fenofibrate pharmaceutical composition having high bioavailability
US10/290,333 US7041319B2 (en) 1997-01-17 2002-11-08 Fenofibrate pharmaceutical composition having high bioavailabilty
US10/665,517 US20040092597A1 (en) 1997-01-17 2003-09-22 Fenofibrate compositions having high bioavailability

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/665,517 US20040092597A1 (en) 1997-01-17 2003-09-22 Fenofibrate compositions having high bioavailability

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US10/288,425 Continuation US6652881B2 (en) 1997-01-17 2002-11-06 Fenofibrate pharmaceutical composition having high bioavailability
US10/290,333 Continuation US7041319B2 (en) 1997-01-17 2002-11-08 Fenofibrate pharmaceutical composition having high bioavailabilty

Publications (1)

Publication Number Publication Date
US20040092597A1 true US20040092597A1 (en) 2004-05-13

Family

ID=9502710

Family Applications (18)

Application Number Title Priority Date Filing Date
US09/005,128 Expired - Lifetime US6074670A (en) 1997-01-17 1998-01-09 Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it
US09/572,330 Expired - Lifetime US6277405B1 (en) 1997-01-17 2000-05-18 Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it
US09/899,026 Expired - Lifetime US7037529B2 (en) 1997-01-17 2001-07-06 Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it
US10/078,500 Expired - Lifetime US6596317B2 (en) 1997-01-17 2002-02-21 Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it
US10/126,875 Expired - Lifetime US6589552B2 (en) 1997-01-17 2002-04-22 Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it
US10/288,425 Expired - Lifetime US6652881B2 (en) 1997-01-17 2002-11-06 Fenofibrate pharmaceutical composition having high bioavailability
US10/290,333 Expired - Lifetime US7041319B2 (en) 1997-01-17 2002-11-08 Fenofibrate pharmaceutical composition having high bioavailabilty
US10/665,518 Abandoned US20040057997A1 (en) 1997-01-17 2003-09-22 Capsules containing fenofibrate compositions
US10/665,517 Abandoned US20040092597A1 (en) 1997-01-17 2003-09-22 Fenofibrate compositions having high bioavailability
US10/665,519 Abandoned US20040057998A1 (en) 1997-01-17 2003-09-22 Fenofibrate compositions
US10/665,522 Abandoned US20040057999A1 (en) 1997-01-17 2003-09-22 Fenofibrate compositions having enhanced bioavailability
US10/665,520 Abandoned US20040058005A1 (en) 1997-01-17 2003-09-22 Processes for producing fenofibrate compositions
US10/665,516 Abandoned US20040058004A1 (en) 1997-01-17 2003-09-22 Suspensions of micronized fenofibrate
US11/723,646 Expired - Lifetime US8329214B2 (en) 1997-01-17 2007-03-21 Process for producing fenofibrate tablets
US11/723,645 Expired - Lifetime US8343540B2 (en) 1997-01-17 2007-03-21 Process for producing fenofibrate tablets
US11/979,065 Abandoned US20080063726A1 (en) 1997-01-17 2007-10-30 Fenofibrate compositions
US11/980,593 Abandoned US20080064759A1 (en) 1997-01-17 2007-10-31 Process for preparing fenofibrate compositions
US12/213,671 Abandoned US20090035379A1 (en) 1997-01-17 2008-06-23 Fenofibrate compositions

Family Applications Before (8)

Application Number Title Priority Date Filing Date
US09/005,128 Expired - Lifetime US6074670A (en) 1997-01-17 1998-01-09 Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it
US09/572,330 Expired - Lifetime US6277405B1 (en) 1997-01-17 2000-05-18 Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it
US09/899,026 Expired - Lifetime US7037529B2 (en) 1997-01-17 2001-07-06 Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it
US10/078,500 Expired - Lifetime US6596317B2 (en) 1997-01-17 2002-02-21 Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it
US10/126,875 Expired - Lifetime US6589552B2 (en) 1997-01-17 2002-04-22 Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it
US10/288,425 Expired - Lifetime US6652881B2 (en) 1997-01-17 2002-11-06 Fenofibrate pharmaceutical composition having high bioavailability
US10/290,333 Expired - Lifetime US7041319B2 (en) 1997-01-17 2002-11-08 Fenofibrate pharmaceutical composition having high bioavailabilty
US10/665,518 Abandoned US20040057997A1 (en) 1997-01-17 2003-09-22 Capsules containing fenofibrate compositions

Family Applications After (9)

Application Number Title Priority Date Filing Date
US10/665,519 Abandoned US20040057998A1 (en) 1997-01-17 2003-09-22 Fenofibrate compositions
US10/665,522 Abandoned US20040057999A1 (en) 1997-01-17 2003-09-22 Fenofibrate compositions having enhanced bioavailability
US10/665,520 Abandoned US20040058005A1 (en) 1997-01-17 2003-09-22 Processes for producing fenofibrate compositions
US10/665,516 Abandoned US20040058004A1 (en) 1997-01-17 2003-09-22 Suspensions of micronized fenofibrate
US11/723,646 Expired - Lifetime US8329214B2 (en) 1997-01-17 2007-03-21 Process for producing fenofibrate tablets
US11/723,645 Expired - Lifetime US8343540B2 (en) 1997-01-17 2007-03-21 Process for producing fenofibrate tablets
US11/979,065 Abandoned US20080063726A1 (en) 1997-01-17 2007-10-30 Fenofibrate compositions
US11/980,593 Abandoned US20080064759A1 (en) 1997-01-17 2007-10-31 Process for preparing fenofibrate compositions
US12/213,671 Abandoned US20090035379A1 (en) 1997-01-17 2008-06-23 Fenofibrate compositions

Country Status (37)

Country Link
US (18) US6074670A (en)
EP (6) EP1273293B1 (en)
JP (6) JP4219988B2 (en)
KR (2) KR100391104B1 (en)
CN (2) CN1278678C (en)
AR (1) AR011411A1 (en)
AT (4) AT291911T (en)
AU (1) AU731964B2 (en)
BR (1) BR9806738A (en)
CA (5) CA2372561A1 (en)
CY (4) CY2396B1 (en)
CZ (1) CZ297251B6 (en)
DE (5) DE69832108T2 (en)
DK (5) DK0952829T3 (en)
DZ (1) DZ2398A1 (en)
EE (1) EE04042B1 (en)
EG (1) EG23978A (en)
ES (5) ES2254569T3 (en)
FR (1) FR2758459B1 (en)
HK (3) HK1023071A1 (en)
HU (3) HU227758B1 (en)
ID (1) ID22528A (en)
IL (1) IL130790D0 (en)
IN (1) IN187906B (en)
IS (1) IS5097A (en)
MA (1) MA26466A1 (en)
NO (2) NO329200B1 (en)
NZ (1) NZ336462A (en)
PL (1) PL194802B1 (en)
PT (4) PT952829E (en)
RU (3) RU2236850C2 (en)
SK (1) SK285847B6 (en)
TN (1) TNSN98009A1 (en)
TR (1) TR199901660T2 (en)
UA (1) UA61096C2 (en)
WO (1) WO1998031361A1 (en)
ZA (1) ZA9800324B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020009496A1 (en) * 1997-01-17 2002-01-24 Andre Stamm Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it
US8968776B2 (en) 2004-07-29 2015-03-03 Ucb, Inc. Composition comprising a benzimidazole and process for its manufacture

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7255877B2 (en) * 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
FR2783421B1 (en) * 1998-09-17 2000-11-24 Cll Pharma Process for the preparation of new galenical fenofibrate formulations, galenic formulations obtained by said process and their applications
SE9803240D0 (en) * 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
AU767154B2 (en) 1998-11-20 2003-10-30 Skyepharma Canada Inc. Dispersible phospholipid stabilized microparticles
EG23951A (en) * 1999-03-25 2008-01-29 Otsuka Pharma Co Ltd Cilostazol preparation
JP4748839B2 (en) * 1999-03-25 2011-08-17 大塚製薬株式会社 Cilostazol preparations
CA2270306C (en) * 1999-04-27 2000-09-26 Bernard Charles Sherman Pharmaceutical compositions comprising co-micronized fenofibrate
US6465011B2 (en) 1999-05-29 2002-10-15 Abbott Laboratories Formulations comprising lipid-regulating agents
US6368620B2 (en) 1999-06-11 2002-04-09 Abbott Laboratories Formulations comprising lipid-regulating agents
US7863331B2 (en) * 1999-07-09 2011-01-04 Ethypharm Pharmaceutical composition containing fenofibrate and method for the preparation thereof
FR2795961B1 (en) * 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Pharmaceutical composition containing micronized fenofibrate, a surfactant and a binding cellulose derivative and process for the preparation
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
FR2803203B1 (en) * 1999-12-31 2002-05-10 Fournier Ind & Sante New galenic formulations of fenofibrate
US6531158B1 (en) * 2000-08-09 2003-03-11 Impax Laboratories, Inc. Drug delivery system for enhanced bioavailability of hydrophobic active ingredients
US8586094B2 (en) 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
US6982281B1 (en) 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
AU2002222567B2 (en) 2000-12-01 2007-05-10 Kyowa Hakko Kirin Co., Ltd. Composition improved in solubility or oral absorbability
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
FR2819720B1 (en) * 2001-01-22 2004-03-12 Fournier Lab Sa New tablets of fenofibrate
ES2284646T3 (en) * 2001-02-22 2007-11-16 Jagotec Ag Statin-fibrate combination with side effects-fed fasting reduced.
WO2002069957A1 (en) * 2001-03-01 2002-09-12 Grelan Pharmaceutical Co., Ltd. Fenofibrate-containing composition
CA2452330C (en) * 2001-07-06 2011-03-22 Lifecycle Pharma A/S Controlled agglomeration
GB0119480D0 (en) * 2001-08-09 2001-10-03 Jagotec Ag Novel compositions
US20030091634A1 (en) * 2001-09-14 2003-05-15 Pawan Seth Delayed release tablet of venlafaxin
US20030118647A1 (en) * 2001-12-04 2003-06-26 Pawan Seth Extended release tablet of metformin
FR2834212B1 (en) * 2001-12-27 2004-07-09 Besins Int Belgique Use of a powder in immediate release pharmaceutical and nutraceutical compositions
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
US20030212138A1 (en) * 2002-01-14 2003-11-13 Pharmacia Corporation Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
MXPA04007438A (en) 2002-02-01 2004-10-11 Pfizer Prod Inc Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials.
DK1487416T3 (en) * 2002-03-26 2010-03-29 Teva Pharma Drug Microparticles
EP2228060A1 (en) * 2002-05-03 2010-09-15 Skyepharma Canada Inc. Oral dosage forms comprising fenofibrate
US6828334B2 (en) * 2002-05-23 2004-12-07 Usv Limited Fenofibrate-cyclodextrin inclusion complexes and their pharmaceutical composition
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20070264348A1 (en) * 2002-05-24 2007-11-15 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
FR2841138B1 (en) * 2002-06-25 2005-02-25 Cll Pharma A solid pharmaceutical composition containing a lipophilic active principle, process for its preparation
EP1539117A4 (en) * 2002-06-28 2005-12-14 Shire Lab Inc Formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability
US20040005339A1 (en) * 2002-06-28 2004-01-08 Shojaei Amir H. Formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability
DE60315840T2 (en) * 2002-07-11 2008-05-15 Pronova Biopharma Norge As A method for reducing the amount of cholesterol in a marine oil using a volatile working fluid
SE0202188D0 (en) * 2002-07-11 2002-07-11 Pronova Biocare As A process for Decreasing environmental pollutants in an oil or a barrel, a barrel or volatile oil environmental pollutants Decreasing working fluid, a health supplement, and an animal feed product
AU2003263480A1 (en) * 2002-09-24 2004-04-19 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of fenofibrate having high bioavailability
ES2594758T3 (en) * 2002-10-23 2016-12-22 Glaxosmithkline Biologicals S.A. Vaccination procedures against malaria
US20040086567A1 (en) * 2002-10-30 2004-05-06 Pawan Seth Bioequivalent composition of itraconazole and a hydrophilic polymer
DE60229450D1 (en) 2002-12-13 2008-11-27 Jagotec Ag Topical nanoparticle-spironolactone formulation
EP1572190B1 (en) * 2002-12-17 2007-04-18 Abbott GmbH & Co. KG Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof
US20040115287A1 (en) * 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
US20080051411A1 (en) * 2002-12-17 2008-02-28 Cink Russell D Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof
US7259186B2 (en) 2002-12-17 2007-08-21 Abbott Laboratories Salts of fenofibric acid and pharmaceutical formulations thereof
US20040142903A1 (en) * 2003-01-16 2004-07-22 Par Pharmaceutical Inc. Bioavailable fenofibrate compositions, methods for treating hyperlipidemia and hypercholesterolemia and processes for the preparation of such compositions
US20040162320A1 (en) * 2003-02-14 2004-08-19 Pawan Seth Solid composition containing nisoldipine a mixture of polyethylene oxides and an antioxidant
FR2851734B1 (en) * 2003-02-28 2006-06-09 Galenix Innovations Process for the manufacture of a pharmaceutical composition in the form of tablets containing a fibrate and tablets obtained by the process
JP4589919B2 (en) * 2003-03-07 2010-12-01 シェーリング コーポレイションSchering Corporation For the treatment of hypercholesterolemia, substituted azetidinone compounds, these formulations and use
EP1606287B1 (en) * 2003-03-07 2013-10-02 Merck Sharp & Dohme Corp. Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
CN100439361C (en) 2003-03-07 2008-12-03 先灵公司 Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US7601756B2 (en) * 2003-06-06 2009-10-13 Snowden Pharmaceuticals, Llc Method of treatment for irritable bowel syndrome
DE10325989A1 (en) * 2003-06-07 2005-01-05 Glatt Gmbh A process for preparing and resultant micropellets and their use
FR2857591B1 (en) * 2003-07-17 2007-11-02 Ethypharm Sa Particles comprising an active ingredient in the form of co-precipitate
EP1653927B1 (en) 2003-08-04 2012-01-11 Bend Research, Inc Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
KR20130103818A (en) * 2003-10-10 2013-09-24 벨로시스 파마슈티컬스 에이/에스 A solid dosage form comprising a fibrate
US20050096391A1 (en) * 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and rosuvastatin
EP1680086A2 (en) * 2003-10-10 2006-07-19 LifeCycle Pharma A/S A solid dosage form comprising a fibrate and a statin
US20070014846A1 (en) * 2003-10-10 2007-01-18 Lifecycle Pharma A/S Pharmaceutical compositions comprising fenofibrate and atorvastatin
US20050096390A1 (en) * 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and pravastatin
US9173847B2 (en) * 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
DE10355461A1 (en) 2003-11-27 2005-06-23 Bayer Healthcare Ag Solid, high bioavailabilty oral formulations of N-substituted 5-chloro-2-thiophene-carboxamide derivative in hydrophilized form, useful for combating thrombo-embolic diseases
US20050142203A1 (en) * 2003-12-30 2005-06-30 Grant Heinicke Oral dosage formulations of active pharmaceutical ingredients and methods of preparing the same
DE102004002761B4 (en) * 2004-01-20 2017-01-05 Daimler Ag Method for operating a drivetrain of a motor vehicle
EP1559419A1 (en) * 2004-01-23 2005-08-03 Fournier Laboratories Ireland Limited Pharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention
FR2868079B1 (en) * 2004-03-29 2007-06-08 Seppic Sa Surfactants in the form of powder used in tablets or capsules METHOD of preparation and compositions containing them
US7244765B2 (en) 2004-06-25 2007-07-17 Cytokine Pharmasciences, Inc Guanylhydrazone salts, compositions, processes of making and methods of using
US8026281B2 (en) * 2004-10-14 2011-09-27 Lupin Atlantis Holdings, S.A. Treating metabolic syndrome with fenofibrate
WO2006060817A1 (en) * 2004-12-03 2006-06-08 Abbott Laboratories Pharmaceutical compositions
CN101098690A (en) * 2004-12-06 2008-01-02 瑞莱恩特医药品有限公司 Omega-3 fatty acids and dyslipidemic agent for lipid therapy
US20060211762A1 (en) * 2004-12-06 2006-09-21 Rongen Roelof M Omega-3 fatty acids and dyslipidemic agent for lipid therapy
CN101094647A (en) * 2004-12-06 2007-12-26 瑞莱恩特医药品有限公司 Stable compositions of fenofibrate with fatty acid esters
DE102004062475A1 (en) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Solid, orally administrable pharmaceutical dosage forms with modified release
CA2593191A1 (en) * 2005-01-14 2006-07-20 Avax Technologies, Inc. Method for producing a vaccine for the treatment of cancer
CN101128189A (en) * 2005-02-25 2008-02-20 弗·哈夫曼-拉罗切有限公司 Tablets with improved drug substance dispersibility
JP2006273849A (en) * 2005-03-02 2006-10-12 Aska Pharmaceutical Co Ltd Fenofibrate containing composition
EP1861087A4 (en) * 2005-03-08 2010-02-10 Reliant Pharmaceuticals Inc Treatment with statin and omega-3 fatty acids and a combination product thereof
EP1707197A1 (en) 2005-03-30 2006-10-04 Teva Pharmaceutical Industries Ltd. Formulations containing fenofibrate and a surfactant mixture
WO2006107411A2 (en) * 2005-03-30 2006-10-12 Teva Pharmaceutical Industries Ltd. Formulations containing fenofibrate and surfacant mixture
AU2005330266A1 (en) * 2005-03-30 2006-10-12 Teva Pharmaceutical Industries Ltd. Improved formulations of fenofibrate containing menthol or PEG/poloxamer
US20060280791A1 (en) * 2005-04-08 2006-12-14 Ju Tzuchi R Pharmaceutical formulations
US20080152714A1 (en) * 2005-04-08 2008-06-26 Yi Gao Pharmaceutical Formulations
US20070185199A1 (en) * 2005-04-08 2007-08-09 Ju Tzuchi R Pharmaceutical formulations
US20070148234A1 (en) * 2005-04-08 2007-06-28 Ju Tzuchi R Pharmaceutical formulations
US20070014853A1 (en) * 2005-07-15 2007-01-18 Ilan Zalit Pharmaceutical dosage form containing novel pharmaceutical granulate
JP2008540644A (en) * 2005-07-15 2008-11-20 テバ ファーマシューティカル インダストリーズ リミティド New granulation method and granulate produced therefrom
US20070014854A1 (en) * 2005-07-15 2007-01-18 Ilan Zalit Novel granulation process
US20070015833A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing menthol
US20070015834A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing PEG/Poloxamer
DE102005047561A1 (en) * 2005-10-04 2007-04-05 Bayer Healthcare Ag Drug delivery system, useful to treat and/or prevent e.g. thromboembolic disease, comprises 5-chloro-N-(((5S)-2-oxo-3-(4-(3-oxo-4-morpholinyl)-phenyl)-1,3-oxazolidine-5-yl)-methyl)-2-thiophene carboxamide with fast release active substance
EP1785133A1 (en) * 2005-11-10 2007-05-16 Laboratoires Fournier S.A. Use of fenofibrate or a derivative thereof for preventing diabetic retinopathy
WO2007075171A1 (en) * 2005-12-28 2007-07-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical formulations of fenofibrate having improved bioavailability
US20070148233A1 (en) * 2005-12-28 2007-06-28 Lerner E I Pharmaceutical formulations of fenofibrate having improved bioavailability
DE602005014258D1 (en) 2005-12-28 2009-06-10 Teva Pharma Pharmaceutical formulations of fenofibrate with improved bioavailability
US20090252790A1 (en) * 2006-05-13 2009-10-08 Novo Nordisk A/S Tablet formulation
US20090074872A1 (en) * 2006-06-26 2009-03-19 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
EP2037888A2 (en) * 2006-06-26 2009-03-25 Mutual Pharmaceutical Company, Inc. Active agent formulations, methods of making, and methods of use
CA2654661C (en) 2006-06-26 2012-10-23 Amgen Inc. Compositions comprising modified lcat and use thereof for treating atherosclerosis
CN101594848B (en) * 2006-09-15 2014-10-29 艾可制药有限公司 Containing particulate pharmaceutically active substance and an emulsifier and a preparation method
US9308175B2 (en) 2006-09-15 2016-04-12 Echo Pharmaceuticals B.V. Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances
EP2089002A1 (en) * 2006-10-13 2009-08-19 Janssen Pharmaceutica, N.V. Phenylalkyl carbamate compositions
WO2008104852A2 (en) * 2007-02-26 2008-09-04 Wockhardt Research Centre Pharmaceutical compositions comprising adsorbate of fenofibrate
CA2677076C (en) * 2007-03-02 2017-09-12 Meda Pharmaceuticals Inc. Compositions comprising carisoprodol and methods of use thereof
US7872560B2 (en) * 2007-03-19 2011-01-18 Abc Taiwan Electronics Corp. Independent planar transformer
UA103304C2 (en) 2007-07-26 2013-10-10 Эмджен Инк. Modified protein of lecitin-cholesterin acyltransferase (lcat)
US20100285126A1 (en) * 2007-08-02 2010-11-11 Rahul Dabre Pharmaceutical compositions of fenofibrate
AU2008303129B2 (en) 2007-09-25 2013-08-01 Solubest Ltd Compositions comprising lipophilic active compounds and method for their preparation
US20090202649A1 (en) * 2008-02-06 2009-08-13 Subhash Gore Fenofibrate formulations
JP5437232B2 (en) 2008-03-11 2014-03-12 あすか製薬株式会社 Solid dispersion and pharmaceutical compositions thereof, and methods for their preparation
MX2011006307A (en) 2008-12-15 2011-10-14 Banner Pharmacaps Inc Methods for enhancing the release and absorption of water insoluble active agents.
FR2940118B1 (en) 2008-12-24 2013-08-09 Ethypharm Sa pharmaceutical formulation of fenofibrate nanonized
US20100159010A1 (en) * 2008-12-24 2010-06-24 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
US8501759B2 (en) 2009-01-02 2013-08-06 Fournier Laboratories Ireland Limited Use of fibrates
US20100173882A1 (en) 2009-01-08 2010-07-08 Lipocine, Inc. Steroidal Compositions
WO2010092925A1 (en) * 2009-02-12 2010-08-19 あすか製薬株式会社 Solid dispersion, pharmaceutical composition comprising the solid dispersion, and processes for producing the solid dispersion and the pharmaceutical composition
KR101374854B1 (en) 2009-05-27 2014-03-19 주식회사 삼양바이오팜 Microspheres with improved bioavailability containing poorly water-soluble drugs, and method for preparing same
US20110217369A1 (en) * 2009-09-03 2011-09-08 Ranbaxy Laboratories Limited Fenofibrate compositions
KR100980752B1 (en) * 2009-12-17 2010-09-07 삼일제약주식회사 Granules comprising fenofibrate adsorbed on carrier surface and pharmaceutical composition comprising the same
KR101202994B1 (en) 2010-04-12 2012-11-21 한미사이언스 주식회사 Oral pharmaceutical composition comprising fenofibric acid and an alkalifying agent
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
GB201118182D0 (en) 2011-10-21 2011-12-07 Jagotec Ag Improvements in or relating to organic compounds
WO2013064853A1 (en) 2011-11-05 2013-05-10 Lupin Atlantis Holdings, S.A. Reduced dose oral pharmaceutical compositions of fenofibrate
WO2013086443A1 (en) 2011-12-08 2013-06-13 Amgen Inc. Agonistic human lcat antigen binding proteins and their use in therapy
US9452107B2 (en) 2012-04-16 2016-09-27 New Jersey Institute Of Technology Systems and methods for superdisintegrant-based composite particles for dispersion and dissolution of agents
US9439860B2 (en) 2012-06-25 2016-09-13 Mylan, Inc. Fenofibrate formulation
US8722083B2 (en) * 2012-06-25 2014-05-13 Mylan, Inc. Fenofibrate formulation
WO2014091318A1 (en) 2012-12-11 2014-06-19 Lupin Atlantis Holdings, S.A. Reduced dose pharmaceutical compositions of fenofibrate
EP2842547A1 (en) 2013-08-27 2015-03-04 Freund Pharmatec Ltd. Improved fenofibrate compositions
CN105636582A (en) 2013-09-18 2016-06-01 乔治城大学 Treating neurodegenerative disease with fenofibrate and analogs thereof
KR101576587B1 (en) * 2014-02-05 2015-12-10 한양대학교 에리카산학협력단 Novel composite of gelatin nanoparticle containing fenofibrate
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
CN104352466A (en) * 2014-11-17 2015-02-18 辰欣药业股份有限公司 Fenofibrate composition and preparation thereof
CN104922078B (en) * 2015-06-23 2018-10-23 上海市计划生育科学研究所 Fenofibrate delayed release pellets, preparation method and application
US20190091333A1 (en) 2017-09-22 2019-03-28 Arcutis, Inc. Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents

Citations (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2953497A (en) * 1953-06-03 1960-09-20 Howard A Press Therapeutic tablets
US4344934A (en) * 1978-11-20 1982-08-17 American Home Products Corporation Therapeutic compositions with enhanced bioavailability
US4412986A (en) * 1977-06-07 1983-11-01 Yamanouchi Pharmaceutical Co. Ltd. Nifedipine-containing solid preparation composition
US4463743A (en) * 1981-12-14 1984-08-07 Brunswick Corporation Capacitor discharge ignition system for internal combustion engines
US4524060A (en) * 1981-05-21 1985-06-18 John Wyeth & Brother Limited Slow release pharmaceutical composition
US4588058A (en) * 1982-09-07 1986-05-13 Regie Nationale Des Usines Renault Device for damping the vibrations of a flexible clutch in wet conditions, notably for torque converter
US4629624A (en) * 1984-01-02 1986-12-16 Laboratoire D'hygiene Et De Dietetique (L.H.D.) Inert matrix based on polycaprolactone for the oral administration of a drug, and method for the preparation of the galenic form comprising this matrix
US4663150A (en) * 1983-04-06 1987-05-05 Elan Corporation P.L.C. Sustained absorption pharmaceutical composition
US4684516A (en) * 1983-08-01 1987-08-04 Alra Laboratories, Inc. Sustained release tablets and method of making same
US4716033A (en) * 1986-03-27 1987-12-29 Warner-Lambert Company Medicament adsorbates with surfactant and their preparation
US4717569A (en) * 1984-06-04 1988-01-05 Sterling Drug Inc. Unit dosage form of sparingly soluble medicaments
US4721709A (en) * 1984-07-26 1988-01-26 Pyare Seth Novel pharmaceutical compositions containing hydrophobic practically water-insoluble drugs adsorbed on pharmaceutical excipients as carrier; process for their preparation and the use of said compositions
US4795643A (en) * 1987-02-02 1989-01-03 Mepha Ag Dornacherstrasse 114 Medicament with a delayed release of active ingredient
US4800079A (en) * 1986-08-08 1989-01-24 Ethypharm Sa Medicine based on fenofibrate, and a method of preparing it
US4806361A (en) * 1984-06-04 1989-02-21 Sterling Drug Inc. Medicaments in sustained release unit dose form
US4895726A (en) * 1988-02-26 1990-01-23 Fournier Innovation Et Synergie Novel dosage form of fenofibrate
US4992277A (en) * 1989-08-25 1991-02-12 Schering Corporation Immediate release diltiazem formulation
US5073379A (en) * 1988-09-07 1991-12-17 Basf Aktiengesellschaft Continuous preparation of solid pharmaceutical forms
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5545628A (en) * 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
US5633015A (en) * 1992-09-03 1997-05-27 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer
US5776495A (en) * 1994-07-26 1998-07-07 Laboratoires Effik Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
US5783215A (en) * 1994-07-08 1998-07-21 Astra Aktiebolag Pharmaceutical preparation
US5824341A (en) * 1994-08-11 1998-10-20 Pharma Pass Composition providing selective release of an active ingredient
US6027747A (en) * 1997-11-11 2000-02-22 Terracol; Didier Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
US6033686A (en) * 1998-10-30 2000-03-07 Pharma Pass Llc Controlled release tablet of bupropion hydrochloride
US6042847A (en) * 1995-05-19 2000-03-28 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Three-phase pharmaceutical form with constant and controlled release of amorphous active ingredient for single daily application
US6048547A (en) * 1996-04-15 2000-04-11 Seth; Pawan Process for manufacturing solid compositions containing polyethylene oxide and an active ingredient
US6096341A (en) * 1998-10-30 2000-08-01 Pharma Pass Llc Delayed release tablet of bupropion hydrochloride
US6117453A (en) * 1995-04-14 2000-09-12 Pharma Pass Solid compositions containing polyethylene oxide and an active ingredient
US6159499A (en) * 1995-09-21 2000-12-12 Pharma Pass Llc Composition containing an acid-labile benzimidazole and process for its preparation
US6180138B1 (en) * 1999-01-29 2001-01-30 Abbott Laboratories Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption
US20020009496A1 (en) * 1997-01-17 2002-01-24 Andre Stamm Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it
US6348469B1 (en) * 1995-04-14 2002-02-19 Pharma Pass Llc Solid compositions containing glipizide and polyethylene oxide
US20050032878A1 (en) * 2001-08-07 2005-02-10 Arthur Deboeck Oral pharmaceutical composition containing a combination pparalpha and a hmg-coa reductase inhibitor

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6655A (en) * 1849-08-21 Eirepboof safe
US9496A (en) * 1852-12-21 Method of measuring cloth on the cloth-beam
US168413A (en) * 1875-10-05 Improvement in hydrants
US58005A (en) * 1866-09-11 Improvement in distilling petroleum and other liquids
US114839A (en) * 1871-05-16 Improvement in apparatus for aerating beer-barrels
US57998A (en) * 1866-09-11 Improvement in broom-heads
US57999A (en) * 1866-09-11 Improved composition for roofing
US92597A (en) * 1869-07-13 Improved counterpoise gun-carriage
US5783A (en) * 1848-09-19 Spinoabdominal supporter
US57997A (en) * 1866-09-11 Improvement in malt-ksln floors
US104060A (en) * 1870-06-07 Improvement in organ-bellows
US58004A (en) * 1866-09-11 Improved lap-joint for belting
US104051A (en) * 1870-06-07 Improvement in handles of sheet-metal spoons, forks
US2776996A (en) * 1955-12-22 1957-01-08 Du Pont Manufacture of beta-methylmercaptopropionaldehyde
CH543472A (en) 1969-01-31 1973-10-31 Orchimed Sa A method for the preparation of phenoxyalkyl carboxylic acids
FR2314917B1 (en) * 1975-06-20 1977-12-02 Rhone Poulenc Ind
DE2966564D1 (en) 1978-11-20 1984-02-23 American Home Prod Therapeutic compositions with enhanced bioavailability and process for their preparation
FR2494112B1 (en) * 1980-11-19 1986-01-10 Laruelle Claude
DE3107933A1 (en) * 1981-03-02 1982-09-16 Cassella Ag Substituted 3-amino-sydnonimines, process for their production and their use
DE3247118A1 (en) * 1982-12-20 1984-06-20 Cassella Ag New substituted 1,4-dihydropyridines, processes for their manufacture and their use as medicines
IT1180507B (en) 1984-06-29 1987-09-23 Roberto Valducci Process for the preparation of etofibrato or substances of equal or similar characteristics, in microgunuli-delay and product obtained with this process
EP0179583A1 (en) 1984-10-04 1986-04-30 Merck & Co., Inc. A system for enhancing the water dissolution rate and solubility of poorly soluble drugs
US4649082A (en) 1985-03-07 1987-03-10 Ppg Industries, Inc. Radiation curable compositions based on radiation curable esters of polyfunctional hydroxyl-containing carboxylic acids
US5385938B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of using glycolic acid for treating wrinkles
US4859703A (en) * 1987-06-15 1989-08-22 Warner-Lambert Company Lipid regulating compositions
DE3807895A1 (en) * 1988-03-10 1989-09-21 Knoll Ag Products containing a calcium antagonist and a lipid-lowering agents
US4961891A (en) * 1988-10-04 1990-10-09 Garlock, Inc. Method of making high compressibility gasket material
US4927639A (en) * 1989-02-02 1990-05-22 Warner-Lambert Company Modified release gemfibrozil composition
GB9015872D0 (en) * 1990-07-19 1990-09-05 Secr Defence Production of ceramic filaments
DE69127275T2 (en) * 1991-06-21 1998-03-12 Ilsan Ilac Ve Hammaddeleri San New galenic procedures for containing omeprazole pellets
FR2692146B1 (en) * 1992-06-16 1995-06-02 Ethypharm Sa stable compositions of microgranules of gastro-protected omeprazole and process for obtaining them.
IT1264020B (en) * 1993-01-28 1996-09-09 Recordati Chem Pharm Process for the preparation of microgranules suitable for suspension in liquids
US5549906A (en) * 1993-07-26 1996-08-27 Pharmacia Ab Nicotine lozenge and therapeutic method for smoking cessation
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
FR2723586A1 (en) 1994-08-11 1996-02-16 Seth Pawan New compositions containing cimetidine and associations deriving
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5905171A (en) * 1995-06-22 1999-05-18 Novus International, Inc. Process for the preparation of 3-(methylthio)propanal
DE19608750A1 (en) * 1996-03-06 1997-09-11 Durachemie Gmbh & Co Kg A process for the preparation of fenofibrate preparations
FR2758461A1 (en) 1997-01-17 1998-07-24 Pharma Pass Pharmaceutical composition having high bioavailability and process for preparing the same
US5952396A (en) * 1997-06-16 1999-09-14 Raychem Corporation Low modulus elastomer
CA2214895C (en) * 1997-09-19 1999-04-20 Bernard Charles Sherman Improved pharmaceutical composition comprising fenofibrate
US6334192B1 (en) * 1998-03-09 2001-12-25 Ronald S. Karpf Computer system and method for a self administered risk assessment
US6368622B2 (en) 1999-01-29 2002-04-09 Abbott Laboratories Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption
GB2363866B (en) * 2000-05-31 2002-11-06 Intamission Ltd Data processing apparatus, method and system
US6375986B1 (en) * 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
DE60138658D1 (en) * 2000-09-29 2009-06-18 Topotarget Uk Ltd Carbamic acid derivatives containing an amide group for the treatment of malaria
EP1414433B1 (en) 2001-08-07 2006-04-12 Laboratoires SMB SA Improved pharmaceutical composition containing a ppar alpha agent and a process for preparing it
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations

Patent Citations (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2953497A (en) * 1953-06-03 1960-09-20 Howard A Press Therapeutic tablets
US4412986A (en) * 1977-06-07 1983-11-01 Yamanouchi Pharmaceutical Co. Ltd. Nifedipine-containing solid preparation composition
US4344934A (en) * 1978-11-20 1982-08-17 American Home Products Corporation Therapeutic compositions with enhanced bioavailability
US4524060A (en) * 1981-05-21 1985-06-18 John Wyeth & Brother Limited Slow release pharmaceutical composition
US4463743A (en) * 1981-12-14 1984-08-07 Brunswick Corporation Capacitor discharge ignition system for internal combustion engines
US4588058A (en) * 1982-09-07 1986-05-13 Regie Nationale Des Usines Renault Device for damping the vibrations of a flexible clutch in wet conditions, notably for torque converter
US4663150A (en) * 1983-04-06 1987-05-05 Elan Corporation P.L.C. Sustained absorption pharmaceutical composition
US4820521A (en) * 1983-04-06 1989-04-11 Eland Corporation P.L.C. Sustained absorption pharmaceutical composition
US4684516A (en) * 1983-08-01 1987-08-04 Alra Laboratories, Inc. Sustained release tablets and method of making same
US4629624A (en) * 1984-01-02 1986-12-16 Laboratoire D'hygiene Et De Dietetique (L.H.D.) Inert matrix based on polycaprolactone for the oral administration of a drug, and method for the preparation of the galenic form comprising this matrix
US4806361A (en) * 1984-06-04 1989-02-21 Sterling Drug Inc. Medicaments in sustained release unit dose form
US4717569A (en) * 1984-06-04 1988-01-05 Sterling Drug Inc. Unit dosage form of sparingly soluble medicaments
US4721709A (en) * 1984-07-26 1988-01-26 Pyare Seth Novel pharmaceutical compositions containing hydrophobic practically water-insoluble drugs adsorbed on pharmaceutical excipients as carrier; process for their preparation and the use of said compositions
US4716033A (en) * 1986-03-27 1987-12-29 Warner-Lambert Company Medicament adsorbates with surfactant and their preparation
US4800079A (en) * 1986-08-08 1989-01-24 Ethypharm Sa Medicine based on fenofibrate, and a method of preparing it
US4961890A (en) * 1986-08-08 1990-10-09 Ethypharm Method of preparing comtrolled release fenofibrate
US4795643A (en) * 1987-02-02 1989-01-03 Mepha Ag Dornacherstrasse 114 Medicament with a delayed release of active ingredient
US4895726A (en) * 1988-02-26 1990-01-23 Fournier Innovation Et Synergie Novel dosage form of fenofibrate
US5073379A (en) * 1988-09-07 1991-12-17 Basf Aktiengesellschaft Continuous preparation of solid pharmaceutical forms
US4992277A (en) * 1989-08-25 1991-02-12 Schering Corporation Immediate release diltiazem formulation
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5633015A (en) * 1992-09-03 1997-05-27 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer
US5783215A (en) * 1994-07-08 1998-07-21 Astra Aktiebolag Pharmaceutical preparation
US5776495A (en) * 1994-07-26 1998-07-07 Laboratoires Effik Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
US5824341A (en) * 1994-08-11 1998-10-20 Pharma Pass Composition providing selective release of an active ingredient
US5545628A (en) * 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
US6117453A (en) * 1995-04-14 2000-09-12 Pharma Pass Solid compositions containing polyethylene oxide and an active ingredient
US6348469B1 (en) * 1995-04-14 2002-02-19 Pharma Pass Llc Solid compositions containing glipizide and polyethylene oxide
US6042847A (en) * 1995-05-19 2000-03-28 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Three-phase pharmaceutical form with constant and controlled release of amorphous active ingredient for single daily application
US6207198B1 (en) * 1995-09-21 2001-03-27 Schwarz Pharma Ag Composition containing an acid-labile omeprazole and process for its preparation
US6159499A (en) * 1995-09-21 2000-12-12 Pharma Pass Llc Composition containing an acid-labile benzimidazole and process for its preparation
US6248355B1 (en) * 1995-09-21 2001-06-19 Schwarz Pharma Ag Pharmaceutical composition containing an acid-labile omeprazole and process for its preparation
US6048547A (en) * 1996-04-15 2000-04-11 Seth; Pawan Process for manufacturing solid compositions containing polyethylene oxide and an active ingredient
US20040058005A1 (en) * 1997-01-17 2004-03-25 Andre Stamm Processes for producing fenofibrate compositions
US20040057998A1 (en) * 1997-01-17 2004-03-25 Andre Stamm Fenofibrate compositions
US20040057997A1 (en) * 1997-01-17 2004-03-25 Andre Stamm Capsules containing fenofibrate compositions
US20020009496A1 (en) * 1997-01-17 2002-01-24 Andre Stamm Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it
US20040057999A1 (en) * 1997-01-17 2004-03-25 Andre Stamm Fenofibrate compositions having enhanced bioavailability
US20020114839A1 (en) * 1997-01-17 2002-08-22 Andre Stamm Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it
US20020168413A1 (en) * 1997-01-17 2002-11-14 Andre Stamm Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it
US20030104060A1 (en) * 1997-01-17 2003-06-05 Andre Stamm Fenofibrate pharmaceutical composition having high bioavailability
US20030104051A1 (en) * 1997-01-17 2003-06-05 Andre Stamm Fenofibrate pharmaceutical composition having high bioavailability
US20040058004A1 (en) * 1997-01-17 2004-03-25 Andre Stamm Suspensions of micronized fenofibrate
US6027747A (en) * 1997-11-11 2000-02-22 Terracol; Didier Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
US6096341A (en) * 1998-10-30 2000-08-01 Pharma Pass Llc Delayed release tablet of bupropion hydrochloride
US6033686A (en) * 1998-10-30 2000-03-07 Pharma Pass Llc Controlled release tablet of bupropion hydrochloride
US6180138B1 (en) * 1999-01-29 2001-01-30 Abbott Laboratories Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption
US20050032878A1 (en) * 2001-08-07 2005-02-10 Arthur Deboeck Oral pharmaceutical composition containing a combination pparalpha and a hmg-coa reductase inhibitor

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020009496A1 (en) * 1997-01-17 2002-01-24 Andre Stamm Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it
US20030104060A1 (en) * 1997-01-17 2003-06-05 Andre Stamm Fenofibrate pharmaceutical composition having high bioavailability
US20040058004A1 (en) * 1997-01-17 2004-03-25 Andre Stamm Suspensions of micronized fenofibrate
US7037529B2 (en) 1997-01-17 2006-05-02 Laboratoires Fournier Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it
US7041319B2 (en) 1997-01-17 2006-05-09 Laboratoires Fournier Fenofibrate pharmaceutical composition having high bioavailabilty
US20070184103A1 (en) * 1997-01-17 2007-08-09 Laboratoires Fournier Process for producing fenofibrate tablets
US20070190136A1 (en) * 1997-01-17 2007-08-16 Laboratoires Fournier Process for producing fenofibrate tablets
US20080063726A1 (en) * 1997-01-17 2008-03-13 Paul Royalty Fund Holdings Ii Fenofibrate compositions
US20080064759A1 (en) * 1997-01-17 2008-03-13 Paul Royalty Fund Holdings Ii Process for preparing fenofibrate compositions
US20090035379A1 (en) * 1997-01-17 2009-02-05 Cabinet Hirsch Fenofibrate compositions
US8329214B2 (en) 1997-01-17 2012-12-11 Laboratoires Fournier S.A. Process for producing fenofibrate tablets
US8343540B2 (en) 1997-01-17 2013-01-01 Laboratories Fournier S.A. Process for producing fenofibrate tablets
US8968776B2 (en) 2004-07-29 2015-03-03 Ucb, Inc. Composition comprising a benzimidazole and process for its manufacture

Also Published As

Publication number Publication date
CY2547B1 (en) 2008-07-02
ES2254569T3 (en) 2006-06-16
AT324885T (en) 2006-06-15
JP2009120623A (en) 2009-06-04
PT2050445E (en) 2013-08-23
PL194802B1 (en) 2007-07-31
NO20100034L (en) 1999-09-16
US6074670A (en) 2000-06-13
DE69834437D1 (en) 2006-06-08
SK96299A3 (en) 2000-08-14
DK2050445T3 (en) 2013-09-08
ES2195308T3 (en) 2003-12-01
EP2050445A3 (en) 2009-09-09
EP1468681A1 (en) 2004-10-20
DE69832108T2 (en) 2006-09-21
ES2241931T3 (en) 2005-11-01
EG23978A (en) 2008-02-26
CY2513B1 (en) 2005-12-23
KR100391104B1 (en) 2003-07-12
CA2372576A1 (en) 1998-07-17
EP0952829A1 (en) 1999-11-03
HU230685B1 (en) 2017-08-28
PL334748A1 (en) 2000-03-13
HK1065952A1 (en) 2011-08-19
US20080063726A1 (en) 2008-03-13
PT1273293E (en) 2005-06-30
PT952829E (en) 2003-07-31
US20020168413A1 (en) 2002-11-14
HU0000808A3 (en) 2001-02-28
CA2219475A1 (en) 1998-07-17
PT1275387E (en) 2006-08-31
EE9900296A (en) 2000-02-15
CN1496738B (en) 2011-03-30
RU2196580C2 (en) 2003-01-20
US6596317B2 (en) 2003-07-22
AT233556T (en) 2003-03-15
CA2448623A1 (en) 1998-07-17
AU731964B2 (en) 2001-04-05
KR100415897B1 (en) 2004-01-24
DZ2398A1 (en) 2003-06-04
CY2396B1 (en) 2004-09-10
KR20000070021A (en) 2000-11-25
US20030104060A1 (en) 2003-06-05
CN1496738A (en) 2004-05-19
DK1273293T3 (en) 2005-06-27
US20070190136A1 (en) 2007-08-16
DE29825080U1 (en) 2004-11-04
JP2009143967A (en) 2009-07-02
FR2758459A1 (en) 1998-07-24
US20020009496A1 (en) 2002-01-24
US20020114839A1 (en) 2002-08-22
EP0952829B1 (en) 2003-03-05
RU2236850C2 (en) 2004-09-27
DK952829T3 (en)
CN1243438A (en) 2000-02-02
NO993519L (en) 1999-09-16
CA2372561A1 (en) 1998-07-17
JP2001511156A (en) 2001-08-07
US20040058004A1 (en) 2004-03-25
UA61096C2 (en) 2003-11-17
JP2005206614A (en) 2005-08-04
AT307576T (en) 2005-11-15
HU227758B1 (en) 2012-02-28
JP4219988B2 (en) 2009-02-04
NO329200B1 (en) 2010-09-13
HK1023071A1 (en) 2003-08-15
CY2560B1 (en) 2008-07-02
AT291911T (en) 2005-04-15
BR9806738A (en) 2000-02-29
US7037529B2 (en) 2006-05-02
US20040057998A1 (en) 2004-03-25
EP1275387B1 (en) 2006-05-03
HU0400409D0 (en) 2004-04-28
DK1275387T3 (en) 2006-08-28
DE69811855D1 (en) 2003-04-10
ID22528A (en) 1999-10-28
DK0952829T3 (en) 2003-06-23
US20030104051A1 (en) 2003-06-05
US20080064759A1 (en) 2008-03-13
CA2372576C (en) 2004-02-10
EE04042B1 (en) 2003-06-16
ES2427252T3 (en) 2013-10-30
HU0000808A2 (en) 2000-12-28
NO993519D0 (en) 1999-07-16
RU2002109746A (en) 2004-03-20
IS5097A (en) 1999-06-29
DE69829591D1 (en) 2005-05-04
US8329214B2 (en) 2012-12-11
EP1273293A1 (en) 2003-01-08
EP2050445B1 (en) 2013-06-26
DE69829591T2 (en) 2006-02-09
HU228849B1 (en) 2013-06-28
IL130790D0 (en) 2001-01-28
CA2448630A1 (en) 1998-07-17
US20070184103A1 (en) 2007-08-09
JP4365343B2 (en) 2009-11-18
AU5336798A (en) 1998-08-07
MA26466A1 (en) 2004-12-20
JP2011173927A (en) 2011-09-08
HK1131051A1 (en) 2014-11-07
DE69834437T2 (en) 2006-11-16
CZ253599A3 (en) 1999-11-17
JP2007326878A (en) 2007-12-20
TR199901660T2 (en) 1999-09-21
EP1273293B1 (en) 2005-03-30
TNSN98009A1 (en) 2005-03-15
CZ297251B6 (en) 2006-10-11
DE69811855T2 (en) 2003-12-18
RU2238089C2 (en) 2004-10-20
SK285847B6 (en) 2007-09-06
EP1275387A1 (en) 2003-01-15
DE69832108D1 (en) 2005-12-01
US6277405B1 (en) 2001-08-21
US7041319B2 (en) 2006-05-09
US20040057999A1 (en) 2004-03-25
ZA9800324B (en) 1998-08-12
US8343540B2 (en) 2013-01-01
EP2050445A2 (en) 2009-04-22
CA2219475C (en) 2002-07-09
EP1273294B1 (en) 2005-10-26
US20040057997A1 (en) 2004-03-25
ES2263714T3 (en) 2006-12-16
AR011411A1 (en) 2000-08-16
DK1273294T3 (en) 2006-03-13
US6652881B2 (en) 2003-11-25
EP1273294A1 (en) 2003-01-08
CN1278678C (en) 2006-10-11
WO1998031361A1 (en) 1998-07-23
US6589552B2 (en) 2003-07-08
FR2758459B1 (en) 1999-05-07
US20040058005A1 (en) 2004-03-25
NZ336462A (en) 2000-09-29
JP4943975B2 (en) 2012-05-30
US20090035379A1 (en) 2009-02-05
IN187906B (en) 2002-07-20

Similar Documents

Publication Publication Date Title
DE60129573T2 (en) A process for the spray-drying of compositions containing fenofibrate
FI79943B (en) Farmaceutisk flerenhetssammansaettning.
CA2123160C (en) Controlled release formulation
AU596183B2 (en) Controlled release bases for pharmaceuticals
CN1303998C (en) Pharmaceutical formulations containing darifenacin
US5283065A (en) Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
EP1109536B1 (en) New solid dose form of nanoparticulate naproxen
RU2343905C2 (en) Solid dosed out forms including fibrat and statin
AU2003301807B2 (en) Nanoparticulate fibrate formulations
KR100365572B1 (en) Production method of sustained-release compositions and pharmaceutical compositions
EP0577504B1 (en) Niacin-containing sustained-release tablets and kits
US20050003002A1 (en) Sustained-release, oral pharmaceutical formulations and methods of making and using same
CN1298317C (en) Tamsulosin tablets
CN100553625C (en) Oral suspension of active principle microcapsules
EP0533297B1 (en) Controlled-release pharmaceutical formulations
EP1242091B1 (en) Use of pharmaceutical compositions comprising oxcarbazepine in the fasted state
FI87424C (en) Foerfarande Foer framstaellning of the fixed nifedipinpreparat, som kan biologically laett tillgodogoeras and which has a foerdroejd effekt
FI90825C (en) Process for the preparation of kefuroksiimiaksetiilikoostumuksen
DK175306B1 (en) A process for the preparation of a pharmaceutical granulate
US5571533A (en) Controlled-release mucoadhesive pharmaceutical composition for the oral administration of furosemide
EP0173210B1 (en) Pellet preparation
JP2916152B2 (en) Drug release rate controlling formulations
EP0375063B1 (en) Granulates for multiparticulate controlled-release oral compositions
US5879705A (en) Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
US8968777B2 (en) Tranexamic acid formulations with reduced adverse effects

Legal Events

Date Code Title Description
AS Assignment

Owner name: PAUL ROYALTY FUND HOLDINGS II, NEW YORK

Free format text: GRANT OF A SECURITY INTEREST IN GRANTOR'S (DEBTOR'S) LICENSE RIGHTS TO GRANTEE (SECURED PARTY);ASSIGNOR:GUARDIAN II ACQUISITION CORPORATION;REEL/FRAME:018385/0257

Effective date: 20060928

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION